Table 3.
Comparison of two subtypes of peripheral neuropathy in EGPA.
| Characteristics | Multiple peripheral neuropathy(n = 33) | Mononeuritis multiplex(n = 18) | P value |
|---|---|---|---|
| Demographics | |||
| Age (year, x ± S) | 49±12.9 | 45±12.8 | 0.404 |
| Gender (male/female, n) | 17/16 | 10/8 | 0.782 |
| Time from allergy to EGPA diagnosis (month), median (IQR) | 24(0, 82.5) | 22(4.8, 150) | 0.593 |
| Disease duration (month), median (IQR) | 6(2,18.5) | 10.5(2.8, 19.3) | 0.453 |
| Time from initial symptoms to EGPA diagnosis (month), median (IQR) | 12(0,48) | 15(0, 51) | 0.96 |
| Clinical manifestation[n (%)] | |||
| Weight loss | 17(51.5) | 8(44.4) | 0.629 |
| Fever | 17(51.5) | 7(38.9) | 0.388 |
| Arthritis or joint pain | 9(27.3) | 3(16.7) | 0.393 |
| Myalgia | 7(21.2) | 7(38.9) | 0.176 |
| Allergic rhinitis | 9(27.3) | 6(33.3) | 0.650 |
| Asthma | 24(72.7) | 16(88.9) | 0.180 |
| Cutaneous vasculitis | 12(36.4) | 14(77.8) | 0.005∗ |
| Renal involvement | 7(21.2) | 9(50.0) | 0.034∗ |
| Digestive tract involvement | 12(36.4) | 8(44.4) | 0.572 |
| CNS involvement | 7(21.2) | 4(22.2) | 1.000 |
| Heart involvement | 14(42.4) | 6(33.3) | 0.525 |
| Ear involvement | 5(15.2) | 3(16.7) | 1.000 |
| Sinusitis | 19(57.6) | 10(55.6) | 0.889 |
| MPO-ANCA | 7(21.2) | 5(27.8) | 0.597 |
| PR3-ANCA | 2(6.1) | 0(0) | 0.287 |
| Eos count (×109/L), median (IQR) | 2.93(0.43,7.42) | 4.40(2.41,9.45) | 0.128 |
| Eos%, median (IQR) | 22.8(9.3,47.8) | 41.0(22.6,49.8) | 0.161 |
| Clinical score | |||
| BVAS (recent 4 weeks,x±S) | 17.82 ±5.587 | 21 ±6.808 | 0.078 |
| FFS ≥1 [n (%)] | 22(66.7) | 9(50) | 0.244 |
PN: peripheral neuropathy; CNS: Central Nervous System; MPO: myeloperoxidase; ANCA: anti-neutrophil cytoplasmic antibody; PR3: protease 3; Eos: eosinophil; BVAS: Birmingham Vasculitis Activity Score; FFS: five factor score; ∗P < 0.05.